DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 200
- Registration Number
- NCT06543511
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 1500
- Registration Number
- NCT06523868
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
The COMPASSION Study
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 200
- Registration Number
- NCT06507930
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
PRISM for Depression and Anxiety in Young Adults With Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT06502483
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Brighton, Massachusetts, United States
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
- Conditions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT06488378
HEME Home Transfusion Program
- Conditions
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 700
- Registration Number
- NCT06487247
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT06475235
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT06468618
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06469307
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Sexual Health and Rehabilitation Online (SHAREonline)
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 84
- Registration Number
- NCT06458049
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States